Progenics Pharmaceuticals Presents Data Validating its Artificial Intelligence Imaging Analysis Technology for Use with PSMA-Targeted SPECT/CT
25 juin 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating...
Progenics Pharmaceuticals Announces Presentation of Updated Data from the Pivotal Trial of AZEDRA® (iobenguane I 131) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
04 juin 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
Progenics Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
31 mai 2018 08h45 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating...
Progenics’ Artificial Intelligence Technology for Automated Analysis of PSMA Targeted Prostate Cancer Images to be Featured at the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
31 mai 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating...
Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform
22 mai 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated bone scan index (aBSI) in men...
Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
09 mai 2018 07h30 HE
|
Progenics Pharmaceuticals Inc.
Pre-Commercial Launch Preparations Underway for AZEDRA® (iobenguane I 131) ahead of U.S. Food and Drug Administration (FDA) July 30th Action DateTop-Line Data from Phase 3 Trial for PSMA-Targeted...
Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection
02 mai 2018 20h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported that its partner Valeant Pharmaceuticals International, Inc. today announced that the U.S. District...
Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9
26 avr. 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and...
Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
25 avr. 2018 17h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and...
Progenics Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
02 avr. 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...